Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of F-genotype Mumps Attenuated Live Vaccine (Human Diploid Cells) in Healthy Infants and Young Children
ChiCTR-IIR-17011282Phase 2Recruiting
- Sponsor
- Hubei Center for Disease Control and Prevention
- Start
- Nov 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mumps vaccine, live (human diploid cell) in mumps (3 arms), sponsored by Hubei Center for Disease Control and Prevention. Primary endpoints: Hemagglutination inhibition antibody seroconversion rate and Neutralizing antibody seroconversion rate. Started Nov 2016; status: recruiting.
02
Drugs
mumps vaccine, live (human diploid cell)
03
Conditions
mumps
Beyond the preview
Go deeper on ChiCTR-IIR-17011282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17011282.